I
INNATE PHARMA
NASDAQ: IPHA (Innate Pharma S.A.)
Last update: 8 minutes ago1.39
-0.07 (-4.79%)
| Previous Close | 1.46 |
| Volume | 32,673 |
| Price / Sales | 27.52 |
| 52 Weeks Range |
| Profit Margin | -245.87% |
| Operating Margin (TTM) | -324.87% |
| Diluted EPS (TTM) | -0.710 |
| Quarterly Revenue Growth (YOY) | -63.70% |
| Total Debt/Equity (MRQ) | 350.86% |
| Current Ratio (MRQ) | 2.60 |
| Operating Cash Flow (TTM) | -6.90 M |
| Levered Free Cash Flow (TTM) | 17.12 M |
| Return on Assets (TTM) | -22.52% |
| Return on Equity (TTM) | -162.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Innate Pharma S.A. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.7 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -0.5 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.43 |
Select this tab to load the latest available analysis.
|
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Institutions | 0.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lion Point Capital, Lp | 30 Jun 2026 | 81,151 |
| Morgan Stanley | 30 Jun 2026 | 43,524 |
| Smartharvest Portfolios, Llc | 30 Sep 2026 | 20,868 |
| Rhumbline Advisers | 30 Jun 2026 | 4,719 |
| Caitong International Asset Management Co., Ltd | 30 Sep 2026 | 74 |
| Farther Finance Advisors, Llc | 30 Sep 2026 | 10 |
| Gamma Investing Llc | 30 Sep 2026 | 9 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |